Mutations that confer drug resistance (Anna Niewiadomska, BV-BRC) (V166L)
 
Mutation: V166L
Position: NC_045512v2:13936-13938
Genomic Size: 3
View DNA for this feature (wuhCor1/SARS-CoV-2)

Reference genome nucleotidesGAA
Mutated nucleotides
DescriptionIn vitro selection of remdesivir-resistant SARS-CoV-2 revealed the emergence of a V166L substitution, located outside of the polymerase active site of the nsp12 protein, after 9 passages. V166L remained the only nsp12 substitution after 17 passages at a final concentration of 10 ┬ÁM RDV,conferring a 2.3-fold increase in EC50. When V166L was introduced into a recombinant SARS-CoV-2 virus, a 1.5-fold increase in EC50 was observed, indicating a high in vitro barrier to RDV resistance.
ReferencesCheckmahomed et al Biorxiv 2021
View table schema

Go to Drug Resistance Mutations track controls

Data last updated at UCSC: 2022-07-01 11:52:39

Description

This track lists amino acid mutations that are known to confer drug resistance against Remdesivir, Sotrovimab, and Nirmatrelvir (Paxlovid). They were sourced with permission from Paul Gordon's website at the University of Calgary and Anna Niewiadomska from the J. Craig Venter Institute, manually input by Max Haeussler.

Display Conventions

Mutations are highlighted on the reference genome. Click or mouse over the mutations to show the full description.

Data Access

The data can be explored interactively with the Table Browser or the Data Integrator. For automated analysis, the genome annotation is stored in a bigBed file that can be downloaded from the download server or the API.

Please refer to our mailing list archives for questions, or our Data Access FAQ for more information.

Credits

Thanks to Anna Niewiadomska from the BV-BRC team at the J. Craig Venter Institute for converting these to coordinates.